Hologic Completes $350M Acquisition of Gynesonics to Expand Minimally Invasive Fibroid Treatment Portfolio

Hologic (NASDAQ: HOLX) recently announced the completion of its acquisition of medical device company Gynesonics, with a final transaction value of approximately $350 million (approximately RMB 2.5 billion).

The centerpiece of this acquisition is the Sonata System, a technology designed for transcervical treatment of symptomatic uterine fibroids, including those causing heavy menstrual bleeding. Combining real-time ultrasound guidance with radiofrequency ablation, the system offers a non-invasive option for both diagnostic intrauterine imaging and therapeutic intervention.

Half of the patients can resume normal activities the day after surgery.

Headquartered in California, USA, Gynesonics has been committed to providing safe and effective minimally invasive treatment solutions for female patients with symptomatic uterine fibroids since its establishment in 2005.

Gynesonics’ flagship product, the Sonata System, is the world’s first and only FDA-approved intrauterine imaging device for diagnosis. Its unique capability lies in enabling transcervical treatment of specific types of symptomatic uterine fibroids, particularly those closely associated with heavy menstrual bleeding (HMB). This is precisely the core reason why Hologic decided to acquire Gynesonics at a significant cost.

It is understood that the Sonata system integrates cutting-edge components, including the Sonata Image-Guided Software (GGS), a radiofrequency generator, an intrauterine ultrasound probe, and a radiofrequency ablation (RFA) handpiece. Leveraging its intelligent guidance capabilities, the system precisely overlays graphics of the ablation zone and thermal safety margins onto ultrasound images, thereby assisting physicians in accurately selecting ablation targets and planning deployment positions to effectively avoid damage to healthy tissue.

The Sonata system integrates intrauterine ultrasound with radiofrequency ablation technology, offering numerous advantages:

① Incision-free surgery: Treatment is performed via a transcervical approach, eliminating the incisions required in traditional surgery to precisely locate and ablate uterine fibroids. The entire procedure is completed within the cervix, leaving no scars and requiring no tissue resection or removal, which significantly reduces surgical trauma and recovery time. Patients can rapidly return to normal daily activities post-procedure, effectively shortening hospital stays and reducing the risk of postoperative complications.

② Uterine Preservation: The Sonata system is designed with full consideration of patients’ fertility needs, enabling them to receive treatment without undergoing hysterectomy.

③ Precision Treatment: Leveraging real-time ultrasound guidance, the Sonata system ensures that radiofrequency energy is precisely delivered to fibroid tissue, achieving efficient ablation.

According to IDE clinical study data provided by Gynesonics, the procedure time for treatment using the Sonata System is typically less than one hour, with the exact duration depending on the number and size of fibroids. The system significantly alleviates symptoms of heavy menstrual bleeding (HMB), reduces the need for surgical reintervention, and enables rapid postoperative recovery, allowing patients to quickly return to their daily lives and work.

Specifically, 52% of patients resumed daily activities on the first postoperative day; 95% experienced significant improvement in heavy menstrual bleeding (HMB) symptoms at 12 months postoperatively; 92% did not require reoperation for HMB within three years; and 88% reported symptomatic improvement after three years.

Currently, the Sonata system has not only received FDA approval but also obtained CE marking, enabling its sale in multiple countries and regions including the European Union, the United Kingdom, Switzerland, and the United States, thereby introducing a novel therapeutic option to the field of global women’s health.

Regarding this acquisition, Brandon Schnittker, President of Hologic’s Surgical Solutions segment, stated that the Sonata system is undoubtedly a strong addition to Hologic’s existing product portfolio. It will provide gynecologic surgeons worldwide with more diverse treatment options, thereby benefiting female patients suffering from heavy menstrual bleeding and uterine fibroids.

Revenue of $4.03 billion, with two acquisitions made within a year

According to Hologic’s financial report for the fourth quarter of fiscal year 2024, the company’s revenue reached $987.9 million in that quarter, representing a 4.5% year-over-year increase. For the full fiscal year 2024, Hologic reported total revenue of $4.03 billion, with first-quarter revenue at $1.0131 billion, second-quarter revenue at $1.0178 billion, and third-quarter revenue at $1.0114 billion.

Robust quarter-over-quarter performance instills confidence in Hologic’s business expansion.

On one hand, Hologic is accelerating its strategic deployment by launching innovative products. In February 2024, Hologic introduced Genius™, the first FDA-cleared novel digital cytology system. The Genius Digital Diagnostics System comprises the Genius™ Digital Imager for image acquisition, the Genius™ Cervical AI Algorithm for image analysis, the Genius™ Image Management Server for image storage, and the Genius™ Review Station for local or remote case review.

On the other hand, Hologic has strengthened its product portfolio through strategic acquisitions. In addition to the acquisition of Gynesonics, Hologic also acquired the UK-based company Endomag in July 2024 for $310 million (approximately RMB 2.2 billion).

Endomag specializes in the development and commercialization of breast surgical localization and lymphatic tracking technologies. Its product portfolio includes Magseed® markers, Magtrace® lymphatic tracer injection, and the Sentimag® platform. Sentimag is a non-radioactive surgical guidance platform that provides tissue localization and breast cancer staging services within a single system. The platform’s probe, which functions similarly to a metal detector, detects Endomag’s magnetic seeds (Magseed®) and liquid tracer (Magtrace®), thereby assisting surgeons in tumor resection and minimally invasive staging procedures.

Magtrace, as a non-radioactive tracer, is specifically developed to optimize the accuracy and efficiency of sentinel lymph node biopsy. It enables surgeons to locate the first draining lymph node most likely to contain cancer cells, thereby determining whether the cancer has spread. The product primarily consists of iron oxide coated with carboxydextran in a saline solution. When injected into the patient’s breast, this magnetically detectable fluid accumulates in the regional lymphatic vessels and migrates to the lymph nodes.

It is worth noting that in December 2022, the FDA formally approved Magtrace and the Sentimag magnetic localization system for use in sentinel lymph node biopsy in breast cancer patients, enabling precise localization of breast cancer and determination of whether the cancer has spread beyond the primary tumor site.